Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Anxiety stories

Oct 14, 2026

Vanda Pharmaceuticals halts social anxiety drug program after Phase 3 failure

Vanda Pharmaceuticals' experimental drug VQW-765 for social anxiety disorder failed the main goal of a late-stage study in female patients, prompting the company to put the program on hold pending further analysis.

Oct 14, 2026·2 sources
00
Sep 21, 2026

Otsuka presents phase 3b results for centanafadine showing improvements in ADHD and anxiety symptoms

Otsuka Pharmaceutical presented new phase 3b clinical trial results for SIMTRIYO (centanafadine) at Psych Congress 2026, demonstrating consistent improvements across ADHD symptoms, anxiety, executive function, and emotional dysregulation in adults with ADHD and comorbid anxiety disorders.

Sep 21, 2026·1 source
00
Sep 15, 2026

Study finds cats linked to increased mental health problems in young children

New research suggests that cats are the only common household pet associated with higher rates of anxiety and behavioral issues in young children, raising questions about pet ownership decisions for families with toddlers.

Sep 15, 2026·2 sources
00
Sep 14, 2026

Definium's LSD-based drug succeeds in third Phase 3 anxiety trial

Definium Therapeutics reported that its oral LSD-based treatment DT120 reduced symptoms of generalized anxiety disorder in a second successful late-stage study, marking the company's third Phase 3 win this year for the candidate.

Sep 14, 2026·2 sources
00
Aug 12, 2026

Definium reports positive Phase 3 results for single-dose DT120 in generalized anxiety disorder

Definium Therapeutics announced its experimental LSD-based pill significantly reduced anxiety symptoms in a late-stage study, meeting the trial's main goal. The results mark the company's second major win in two months and sent shares up more than 20% in premarket trading.

Aug 12, 2026·2 sources
00
Aug 7, 2026

Study Reveals How Early-Life Stress Leaves Molecular 'Scar' in Brain Cells

Researchers at Washington University have discovered that severe childhood stress creates lasting changes to DNA packaging inside brain cells, forming a molecular memory of trauma that makes individuals more vulnerable to anxiety, depression, and mood disorders when facing stress as adults.

Aug 7, 2026·4 sources
00

Study Reveals How Early-Life Stress Leaves Molecular 'Scar' in Brain Cells

Researchers at Washington University have discovered that severe childhood stress creates lasting changes to DNA packaging inside brain cells, forming a molecular memory of trauma that makes individuals more vulnerable to anxiety, depression, and mood disorders when facing stress as adults.

Aug 7, 2026·5 sources
00
Aug 6, 2026

Vistagen Reports Positive Safety and Efficacy Results for Fasedienol in Social Anxiety Disorder Study

Vistagen announced topline results from a repeat dose study of fasedienol for acute treatment of social anxiety disorder, showing favorable safety and tolerability profiles along with efficacy signals across primary and secondary endpoints in both repeat and single dose administrations.

Aug 6, 2026·1 source
00
Aug 4, 2026

Wearable Technology Advances Mental Health Monitoring with New Fingertip Sensors and AI Integration

Researchers demonstrate fingertip sensors can identify physical patterns linked to stress, anxiety and depression, while major wearable companies including Whoop, Oura, and Apple expand into healthcare applications. Amae Health partners with Google Health to integrate Fitbit and voice biomarkers for precision psychiatry.

Aug 4, 2026·3 sources
00
May 23, 2026

Global Mental Health Disorders Affect 1.2 Billion People, Nearly Double Since 1990

A new study found that nearly 1.2 billion people had a mental disorder in 2023, representing a 95.5% increase since 1990, highlighting a significant global mental health crisis.

May 23, 2026·1 source
00
Apr 18, 2026

Xanax Recalled Nationwide Over Failed Quality Specifications

A widely used anxiety medication (Xanax) is being pulled from shelves nationwide due to failed dissolution specifications, according to the FDA.

Apr 18, 2026·1 source
00

Top claims

  • ▪Vanda Pharmaceuticals put the VQW-765 development program on hold while conducting a review of the complete VQW-765 trial dataset
  • ▪The Phase 3 trial results for VQW-765 failed to confirm findings from an earlier mid-stage trial of VQW-765 that had suggested the drug could reduce social anxiety symptoms
  • ▪Vanda Pharmaceuticals designed the Phase 3 study, announced on October 14, 2026, to confirm earlier mid-stage trial results for VQW-765 in patients with social anxiety disorder

Subtopics

Drug Approval and Clinical Trials6Drug Policy, Pricing & Approval6Mental health5Mental Health & Wellbeing5Clinical evaluation4Clinical Trial Design & Evaluation4Depression4Brain health & dementia researchers2Clinical trials2Drug safety2Epigenetics experts2LSD2Psychedelic clinical research & trials2Psychedelic policy & regulation2Stress, Burnout & Well-being2Trauma & PTSD2ADHD1AI assistants & chatbots1Biomarkers & bloodwork testing1Neurodiversity & Cognitive Function1Psychedelic-assisted therapy1Public healthcare1Wearables & Health Tracking1Women’s mental health1

Related timelines

Iran War

209 stories

Strait of Hormuz blockage

148 stories

Trump administration

161 stories

Congress

110 stories

Crypto hacks

100 stories